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ABSTRACT 
Objective 
To determine the reasons for the change or modification in the first line HAART 
regimen (1a and 1b) in HIV positive patients at the Thusong CCMT site. 
Methods 
This study is a quantitative descriptive study using a standardized data 
collection tool to extract retrospective data from medical records. 
Subjects 
Subjects for this study included patients 18 years or older attending the Thusong CCMT 
site, which were started on HAART regimens 1a or 1b and were on treatment for at 
least 6 months. The final sample size evaluated was 257 patients. 
Results 
There was a high rate (43%) of change or modification of the first line HAART 
regimen. Majority of the patient’s (72%) had their regimen modified due to side effects 
of the drugs and only a small number (9.7%) of patients had a complete change in the 
regimen due to virological failure. Stavudine (d4T) associated lipodystrophy was the 
most common side effect (45.5%) followed by peripheral neuropathy (16.7%), leading 
to treatment modification.  
 
Conclusion 
The rate of modification or change of first line HAART regimen, at Thusong CCMT, 
was fairly high (42.6%), and the most common reason for the modification or change 
was drug side effect of stavudine (d4T). 
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Introduction 
 
According to the World Health Organisation (WHO) 0.6% of the world’s population 
were infected with HIV in 2005.
1
 The number of people living with HIV worldwide has 
continued to grow and in 2008 reaching an estimated 33.4 million.
1 
An estimated 5.6 
million people were living with HIV and AIDS in South Africa in 2009, more than in 
any other country.
2
 
 
It is estimated that 2 million (1.7 million-2.4 million)
 
deaths due to AIDS-related 
illnesses occurred worldwide in 2008.
1 
In 2009, an estimated 310,000 South Africans 
died of the Acquired Immune Deficiency Syndrome (AIDS). The prevalence of Human 
Immunodeficiency Virus (HIV) amongst people aged between 15-49 years was 17.8%.
2
 
Young people accounted for around 40% of all new adult HIV infections world wide.
2
 
Sub-Saharan Africa is the most affected region with 67% of the population living with 
HIV.
2 
Treatment with highly active anti-retroviral therapy (HAART) increases the life 
expectancy of people infected with HIV.
1
 Even after HIV has progressed to diagnosable 
AIDS the average survival time with anti-retroviral (HAART) therapy (as of 2005) is 
estimated to be more than 5 years.
1
 According to a WHO report in 2009, without 
HAART, death normally occurs within a year.
1 
HAART treatment reduces both 
mortality and morbidity due to HIV. The impact of the AIDS epidemic is reflected in 
the dramatic change in South Africa’s mortality rate. 3 The overall number of annual 
deaths increased sharply from 1997, when 316,559 people died, to 2006 when 607,184 
people died. In 2006, 41% of these deaths were from the 25-49 years age group, 
whereas in 1997, this age group accounted for only 29% of the deaths.
3  
According to the South African National Antiretroviral Treatment Guidelines (first 
edition 2004) there were two recommended HAART regimens. The first line therapy 
was called Regimen 1 and second line therapy was called Regimen 2. The first line 
regimen was further divided into 2 regimens, Regimen 1a and Regimen 1b. Regimen 
1a was intended for use on all patients who qualified to be on HAART, except 
pregnant women, and 1b was primarily intended for pregnant women.
4
 The 3 drugs  
used as Regimen 1a were d4T (stavudine), 3TC (lamivudine) and Efv (efavirenz), and 
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the 3 drugs used in Regimen  1b are d4T, 3TC and  NVP (nevirapine). Regimen 2 
consists of 3 drugs - AZT (zidovudine) and ddI (didanosine) and lopinavir/ ritonavir. 
 
The HAART regimen can be modified by changing at least one antiretroviral used in 
the initial regimen, or it can be changed by simultaneously stopping all three 
antiretroviral drugs used in the initial HAART regimen and replacing them with a 
new regimen that was not used before. Reasons that can be used to modify or change 
HAART therapy despite good adherence are drug side effects and virological failure.
4
  
 
In a study conducted in The Royal Free Hospital in London UK, 44.4% of patients 
had their HAART regimen changed.
5 
In 29.1% of these patients, the reason was 
immunological or virological failure and in 44.4% the changes were due to toxicities, 
patient’s choice or poor compliance.5 In this particular study it was also found that a 
total of 26.6% of patients discontinued their HAART.  
 
In a Swiss HIV Cohort Study, it was found that 47% of patients presented with 
clinical adverse events,
6
 and this subsequently lead to a change in the HAART 
regimen. In a study conducted in India,
 
where 77% of patients were started on first 
line regimens, similar to the ones we were using in South Africa, it was found that the 
most common reason for modifying the treatment was a drug-related adverse event 
(64%).
7
 In this study it was also found that in 19% of cases, the cost of the drugs was 
the reason leading to treatment discontinuation.  
 
There is not much data available on the reasons for the discontinuation or 
modification of HAART amongst the Sub-Saharan African populations. At the 
Mulago Hospital in Kampala, Uganda it was found that most common reasons for the 
discontinuation of treatment was cost, drug toxicities, and the fact that the drugs were 
out of stock,
9
 whereas in South Africa drug cost and non-availability of the drugs is 
not usually an issue in the public sector. At the Mbagathi District Hospital in Nairobi, 
Kenya
 
 it was found that the most common reasons to modify the drug regimen was to 
avoid potential or real side effects
 
of the drugs.
8
 Lipodystropy,  lactic acidosis and 
then peripheral neuropathy were among  the most common side effects experienced 
Stellenbosch University  https://scholar.sun.ac.za
6 
 
by patients, which were related to d4T (stavudine). All the patients had stavudine 
changed to AZT (zidovudine) or tdf (tenofovir). 
8 
 
In a study done at two Primary Care Treatment programmes in Khayelitsha and 
Nyanga in Cape Town South Africa, 44% of patients included in the study were 
started on regimen 1a and 31% on regimen 1b.
10
 The largest number of drug 
substitutions due to toxicity was in patients on d4T (20.8%) that included 
lipodystrophic body changes (9.0%), peripheral neuropathy (6.2%) and symptomatic 
hyperlactataemia (5%). A large proportion of individuals (7.6%) were taken off NVP 
because of hypersensitivity reactions and the least likely drug to be substituted was 
Efv (1.9%). The main drug contributing to toxicities and side effects such as 
lipodystrophy, peripheral neuropathy and hyperlactataemia was d4T.  
While I was working at the Thusong CCMT site in the West Rand District of 
Johannesburg in the Gauteng province, I noticed that after a few months of starting on 
the HAART Regimens patients often had their regimen modified or changed to another 
regimen. This motivated me to study the circumstances for the modification or change 
in the initial HAART Regimen and I conducted this study on the patients whose 
treatment were modified or changed. 
Aim 
To determine why HIV positive patients on HAART Regimen 1 needed a 
modification or change in the regimen. 
Objectives 
1. To determine the age and gender of patients whose HAART regimen was 
changed or modified. 
2. To determine the percentage of patients with Regimen 1 modification or change. 
3. To determine the reasons for the change or modification in Regimen 1. 
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Methods 
 
Study Design 
This study was a descriptive quantitative study using a standardized data 
collection tool to extract retrospective data from medical records. 
Study Site 
The study was conducted at the Thusong CCMT (comprehensive care, management and 
treatment) site in Kagiso, Johannesburg. The CCMT was established in 2006 in a black 
township with an adult population of 19,950 individuals and serves the needs of patients 
from Kagiso and the surrounding areas. The CCMT is open from Monday to Friday 
08h00-16h00. At the centre, a doctor is available three days a week (i.e. Tuesday, 
Wednesday and Thursday) and on the other two days, there is a professional nurse 
available. 
In South Africa, the National Department of Health guidelines for HAART treatment 
were changed in April 2010 and introduced tdf as first line treatment in place of d4T. 
The change in regimen at this point significantly changed the side effect profile of 
patients on HAART Regimen 1.  
Study Population and sampling  
The study population included   all patients attending the clinic from 01 July 2006 until   
30 June 2011. A total of 603 HIV infected patients were included in the sample without 
the need for any sampling. 
 Inclusion criteria were: 
 Patients over the age of 18 years. 
 Patients started on HAART Regimen 1.  
 Patients who were on HAART for more than 6 months. 
  Patients who had their initial regimen changed or modified. 
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Exclusion criteria were: 
 Patients below the age of 18 years. 
 Patients referred from another CCMT site. 
 Patients who were started on a mixed regimen other than regimen 1a and 1b. 
 Patients who were started on a tdf based Regimen 1 according to The National 
Department of Health (NDOH) recommendations from April 2010. 
Data Collection 
The files of all 603 patients eligible to partake in the study were included in the study. 
In patients with a regimen change the reason/s for changing the patient’s HAART 
regimen, as recorded in the patients file, was collected and analyzed. The following data 
was collected from the patient’s record: 
 Age 
 Gender 
 Initial HAART regimen  
 The change or modification in the regimen 
 Reason/s why the regimen was changed 
Lipodystrophy was recorded as sudden increase in the weight (body mass index), 
increase in the size of stomach or breast, fat deposition at the back between the 
shoulders below neck (buffalo hump) and  thinning of face (facial wasting), limbs and 
buttocks. Peripheral neuropathy was recorded as numbness, weakness, burning pain 
(mostly at night), and pins and needles especially in the feet and hands. Virological 
failure was recorded as a sustained increase of >1000 copies/ml in two consecutive 
reading 3 months apart in spite of good adherence. 
 
Data Analysis 
The data was analysed by using the Epi-info version 3.2 programme developed by the centre 
for disease control in Atlanta, Georgia. Percentages (%) and frequencies (n) of the entire 
sample were calculated for the age categories, for male and female gender, for the initial 
HAART regimen started and for the reasons for treatment modification or change. The mean, 
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median and modal ages were calculated for both male and female gender. Significance testing 
at done at a 0.05 level and relevant p-values were calculated. 
Ethical Consideration 
Strict procedure of confidentiality and anonymity were observed throughout the study. 
Only people directly involved in data collection had access to the patient’s medical 
records. No names or identification numbers were recorded at any point as part of data 
analysis or reporting.  There were no personal risks, harms or dangers to the lives of the 
patients whose records were included in the study. There was no direct involvement of 
the patients therefore a  waiver of informed consent was obtained.  Permission and 
approval for the study were applied for and obtained from both the office of the Director 
Health for the West Rand District Council in Gauteng and the Health Research Ethics 
Committee (HREC) of the Stellenbosch University on 10 May 2011. (Ethics Reference 
No. N11/04/137) 
Results 
At the time of the study a total of 1550 patients were attending the CCMT for their 
antiretroviral treatment but only 603 patients met the inclusion and exclusion criteria. Of 
these 603 patients, only 257 (42.6%) patients had modified or changed their regimens.  
Demographic profile 
For this study the age of the patients was further categorized into four groups i.e. old age (> 
60yrs), older middle age (40-59 yrs), young middle age (25-39 yrs) and young adults (18-
24yrs). Table 1 below shows the distribution of patients by age categories. For female 
patients the mean age was 38 yrs, the median age was 38 yrs, and the modal age was 31yrs. 
For male patients the mean age was 41 yrs, the median age was 41yrs, and the modal age was 
45 yrs.  
Table 1: Distribution of patients by age categories. (N= 257) 
 Age  Categories Frequency (n) Percentage (%) 
Young  adult  age (18-24 yrs) 12 4.7% 
Young  middle age (25-39 yrs) 128 49.8% 
Older middle age ( 40-59 yrs) 114 44.4% 
Old age (>60 yrs) 3 1.1% 
Total 257 100% 
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From Table 1 above it can be seen that almost half of the patients 128 (49.8%) were in the 
young middle age category. In the older middle age there were 114 (44.4%). Therefore, it can 
be stated that the majority of patients (94.2%) are aged between 25-59 yrs, and only 4.7% are 
in the young adult category and very few patients 1.1% are in the old age category.  
 
Table 2 below shows the distribution of patients by male and female gender. From Table 2 it 
can be seen that more than two thirds of the patients 173 (67.3%) were females and the rest 
84 (32.7%) were males. 
 
Table 2: Frequencies (n) and percentages (%) of patients by gender. (N= 257)  
Gender  Frequency (n) Percentage (%) 
Male  84 32.7% 
Female 173 67.3% 
Total 257  100.0%  
Figure 1 below shows the frequency (n) distribution of patients by age categories and gender 
variables. (N=257) 
 
Figure 1 Frequency (n) distributions of patients by age categories and gender variables. 
(N=257) 
Figure 1 above shows the distribution of patients by age categories in male and female 
gender. The group with the biggest difference between male and females is the young middle 
aged group (25-39 yrs).  
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Initial regimens 
Table 3 below shows the distribution of patients on the initial regimens (N=257). From Table 
3 we see that the majority of the patients (94.9%) were initially stated on regimen 1a (d4T + 
3TC + EFV). 
Table 3: Frequencies (n) and percentages (%) of the patients on the initial regimens. (N=257) 
Regimen Started Frequency (n) Percentage (%) 
1a 244 94.9% 
1b 13 5.1% 
Total 257 100.0% 
 
 
Table 4 shows the distribution of the patients on the initial regimens started by age 
categories (N=257). Of the patients on regimen 1a, 122 were from the young middle age 
group and 109 were from the older middle aged group.  There were no patients on regimen 
1b in the older age group. 
Table 4:  Frequency (n) of patients by age categories and initial regimen started (N=257) 
AGE CATEGORIES 
INITIAL REGIMEN 
STARTED   
  1a 1b Total 
Young adult (18-24 yrs) 10 2 12   (4.7%) 
Young middle age (25-39yrs) 122 6 128 (49.8%) 
Older middle age (40-59 yrs) 109 5 114 (44.4%) 
Old age (>60 yrs) 3 0 3     (1.1%) 
TOTAL 244 (95%) 13 (5%) 257 (100%) 
 
Table 5 shows the distribution of patients by their initial regimens and gender.  From the 
patients who were started on regimen 1a, 161(65.98%) were females and 83 (34.02%) were 
males. 
Table 5: Frequency (n) of patients by gender and initial regimen started  (N=257) 
GENDER 
INITIAL TREATMENT 
STARTED 
   1a 1b TOTAL 
FEMALE 161 12 173 (67.3%) 
MALE 83 1 84   (32.7%) 
TOTAL 244 13 257 (100%) 
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Reasons for change or modification of regimens 
The reasons for the change in the initial treatment are listed in Table 6. We see that the major 
cause of the treatment modification was lipodystrophy (45.5%), followed by peripheral 
neuropathy (16.7%), pregnancy (11.7%) and virological failure (9.7%). Out of 257 patients 
who had their regimen changed or modified 224 (87.2%) had modification of their initial 
regimen and 33 (12.8%) had a complete regimen change. 
 
Table 6: Reasons for the change or modification of initial treatment. (N=257) 
Reasons for Change Frequency  (n) Percentage (%) 
Lipodystrophy 117  45.5% 
Peripheral neuropathy 43  16.7%  
Pregnancy 30  11.7%  
Virological Failure 25  9.7%  
Lipodystrophy and Peripheral Neuropathy 12  4.7%  
Gynaecomastia 6  2.3%  
Nightshift/Shift worker 6  2.3%  
Defaulted Treatment 6 2.3% 
No reason 4  1.6%  
Hypertension 3  1.2%  
Bipolar mood disorder 1 0.4% 
Confusion 1 0.4% 
Hallucinations 1  0.4%  
Lactic acidosis 1  0.4%  
Nightmares 1  0.4%  
Total 257  100.0%  
 
In Table 7 we see that of the 257 patients in the study, 185 (71.9%) patients had d4T 
substituted. The d4T was changed to tdf in 95 (36.9%) patients which is in line with the 
new guidelines that stated “patients started on d4T should remain on d4T if well 
tolerated, early switching with any toxicity, substitute with tdf if any side effects to d4T 
or at high risk of toxicity i.e. high BMI, low Hb or older female.” d4T was changed by 
AZT in 64 (24.9%) patients prior to the availability of tdf with the new guidelines or 
because tdf was contraindicated. The major reasons for the change of d4T to AZT were 
lipodystrophy, peripheral neuropathy and gynaecomastia. The change of Efv to NVP 
was either because the patient became pregnant or she was planning to get pregnant. 
Only a few male patients had their Efv changed to Aluvia because of the side effects of 
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Efv (nightmares), or because they started working nightshift or became shift workers. 
Virological failure was the only reason related to a full regimen change. 
 
Table 7: Frequency (n) of patients with treatment modification or change by gender. (N= 
257) 
REGIMEN MODIFIED FEMALE MALE TOTAL 
d4T TO ABC 1   (0.8%) 0 (0%) 1    (0.4%)  
d4T TO AZT 38 (31.6%) 26 (40%) 64 (24.9%) 
d4T TO AZT TO tdf 18 (15%) 7 (10.7%) 25 (9.7%) 
d4T TO tdf 63 (52.5%) 32(26, 7%) 95 (36.9%) 
TOTAL 120 (46.6%) 65 (25.3%) 185 (71.9%) 
    Efv TO ALUVIA 5 (15.6%) 3 (42.9%) 8    (20.5%) 
Efv TO NVP 27(84.3%) 4 (57.1%) 31 (79.5%) 
TOTAL 32 (82%) 7   (18%) 39  (15.1) 
    REGIMEN CHANGED 
   FULL REGIMEN CHANGED 21 (8.2%) 12 (4.6%) 33 (12.8%) 
 
 
The reasons for the change or modification of the initial treatment were categorised into four 
main groups: 
(1) Side effect of drugs included confusion, gynaecomastia, hallucination, lipodystrophy, 
lactic acidosis, peripheral neuropathy, and nightmares.  
(2)  Patient’s personal reasons included shift work and night shift worker. 
(3)  Virological failure. 
(4)  Other reasons included bipolar mood disorder, hypertension and those patients where no 
reason was written in the file  
 
Table 8 below shows the frequency (n), percentages (%) of the various categories for reason 
for modification or change of the initial regimen. 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
14 
 
 
Table 8 shows that the major causes for the treatment change or modification was side effects 
of the anti-retroviral drugs (72.4%) followed by patient’s reasons (16.3%) and virological 
failure(9.7%). 
 
Figure 2 shows the frequencies (n) of the categories of reason for regimen 
change/modification by age categories. 
 
Figure 2: Frequency (n) of patients by age categories and reasons for treatment change 
categories. (N=257) 
 
Figure 2 clearly shows that the side-effects due to drugs, is the main reason for treatment 
change or modification in all categories, except in the young adult group, where it is patient’s 
reason.   
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Figure 3 shows that in both males and females, side effect of drugs was the commonest 
reason for modifying or changing the regimen.  
 
 
 
 Figure 3: Frequency (n) of patients by gender and categories for reasons for treatment 
modification. (N=257) 
Discussion 
Key findings 
The study confirms the rationale for changing the HAART guidelines in 2010 in that the 
largest number of substitutions were for side effects associated with d4T. The need for these 
substitutions has been largely removed by the use of tdf. Efv required substitution in a much 
smaller number of patients and no substitutions were recorded relating to side effects caused 
by 3TC or NVP. The number of unexplained or inappropriate regimen changes appeared 
small with only 1.6% of cases having no identifiable reason. 
The data showed that majority (49.8%) of the patients were in the young middle age, 
followed by old middle age (44.4%), that means predominance of the patients (94.2%) were 
between the ages of 25-59 yrs and this age group represents the sexually active population of 
the community. Though the majority of patients were from the population of child bearing 
age, they were started on regimen 1a except those who were already pregnant or planning to 
get pregnant at the time of starting the treatment.  
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In this study predominantly more patients who had their regimen changed were female 
(67.3%) than males (32.7%). Similar findings were obtained in a study conducted in 
Durban.
11  
 
Among the reasons for the change or modification of HAART regimen 1, lipodystrophy 
stands out clearly as the most common reason (72.4%), followed by peripheral 
neuropathy, pregnancy and virological failure. Stavudine (d4T) was the main drug that 
was changed because of the side effects experienced by the patients. Out of 257 
patients, d4T was changed in 185 patients (71.9%) and lipodystrophy was the main 
reason (45.5%) for the change of d4T. These findings were similar to a study in Royal 
Free Hospital, London, UK. In a study done in Mbagathi District Hospital, Kenya,
 
hyperlactataemia/lactic acidosis was the 2
nd
 main adverse drug reaction whilst in my 
study; it was identified in only one patient.
12 
 The reason for this could be that lactic 
acidosis was under diagnosed and under reported or that the patients were transferred to 
hospitals with their CCMT records. 
 
Limitations of the study 
1. Due to the change in the SA National HAART protocol (1 December 2009) and 
the introduction of a tdf (tenofovir) based regimen as first line treatment, more 
patients were started on tdf, 3TC and Efv or NVP (1 April 2010) and that was 
the reason why only 603 (38.9%) patients at the Thusong CCMT met the 
inclusion and exclusion criteria. 
2. The study was conducted at only one CCMT site with predominantly black 
African population which may limit generalization of the results to other CCMT 
site with mixed population. 
3. Record keeping was not up to standard and missing or inaccurate information in 
the files could have influenced the accuracy of the results. 
4. Although the findings of the study have to some extent been super ceded by the 
removal of d4T, the study does support the rationale for this policy change and 
the need for all countries to move away from first-line d4T based regimens. 
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Recommendations 
1. The introduction of HAART drugs to large number of people in countries should 
be preceded with clinical trials for a longer time in Cohort studies to determine 
the short and long term side effects to prevent the problems experienced by 
patients with d4T as 1
st
 line HAART. 
2. Continued update of health care personnel’s knowledge of side effects in order to 
detect them early and change the regimen.  
3. To continue with improved counselling, health promotion, use of condoms and 
early detection and treatment of opportunistic infection. To detect risky 
behaviour early and to prevent subsequent virological failure  that will necessitate 
regimen changes.    
4. Future/ follow on study to track whether regimen changes are less with the use of 
tdf as initial regimen as compared to d4T. 
CONCLUSION 
Out of 257 patients included in the study the majority were females 173 (67.3%) and males 
constituted only 84 (32.7%). Patients included in the study were 18 years or older and the 
majority 128 (49.8%) belonged to young middle age (25-39 yrs) followed by 114 (44.4%) 
older middle age (40-59yrs), in keeping with the general trends in HIV prevalence studies.
2 
There was a high percentage (42.6%) of treatment modification or change in the 
HAART regimen among the patients at Thusong CCMT site who were started on 
regimen 1 (d4T, 3TC and Efv or NVP) as first line treatment during the period July 
2006 – June 2011.  
 
The main drug that was modified in the regimen was d4T (71.9%) mainly because of 
side effects, lipodystrophy (45.5%) and peripheral neuropathy (16.7%). Efv was 
changed to NVP (12%) either because the patient became pregnant or she was planning 
a pregnancy. Only a few male patients had their Efv changed to Aluvia (3.1%) because 
of the side effect of Efv (nightmares) or because they had started working night shift or 
became shift workers. 
An amount of 2.3% patients defaulted treatment, and 9.7% had virological failure that 
resulted in the change of their initial HAART regimen. 
Stellenbosch University  https://scholar.sun.ac.za
18 
 
References 
1 UNAIDS, World Health Organisation.2009.2009 AIDS epidemic Update Available 
from: http://data.unaids.org/pub/report/2009/2009_epidemic_update_en.pdf 
2 UNAIDS (2010) ‘UNAIDS report on the global AIDS epidemic: 
www.unaids.org/globalreport/global_report 
3 Statistic South Africa (2008, October),’Mortality and cause of death in South Africa, 
2006: findings from death notification’ 
4 National Antiretroviral Treatment Guidelines. National Department of Health: 
Pretoria, 2004, Available from www.hst.org.za.  
 
5 Mocroft A, Youle M, Moore A, Sabin CA, Madge S. Reasons for modification 
and discontinuation of antiretroviral: results from a single treatment centre. 
Aids. 2001, 15(2):185-194.    
6 Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H. Prevalence of 
adverse events associated with potent antiretroviral treatment: Swiss HIV 
Cohort Study. Lancet 2001, 358(9290): 1322-1327. 
7 Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, 
Saqhavam S, Flanigan TP, Carpenter CC, Solomon S, Mayer KH. Reasons for 
modification of generic highly active antiretroviral therapeutic regimens 
among patients in Southern India. JAcquir Immune Defic. Syndr. 2006 Jan 1; 
41(1):53-8. 
8 Kocholla L.  Wangai M. Kusu N. Manudu J. Thuo M. Reasons for switching highly 
active antiretroviral therapy (HAART) regimens among HIV/AIDS patients in low-
resource settings: the case of Mbagathi District Hospital Kenya: 
http://www.ias2007.org-pag-Abstracts.aspxAID=3598 
9 Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E. 
Discontinuation and modification of highly active antiretroviral therapy in HIV-
infected Ugandans: prevalence and associated factors. J Acquir Immune 
DeficSyndr.2007 Jun 1;45(2):218-23. 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
10 Boulle A, Orrell C, Kaplan R, Van Cutsem  G, McNally M. Hilderbrand K. 
Substitutions due to antiretroviral toxicity or contraindication in the first 3 
years of antiretroviral therapy in a large South African cohort. AntivirTher. 
2007; 12(5):753-60.   
11 Ramirez-Avila L, Nixon K , Noubary F, Giddy J. Routine HIV testing in adolescents 
and young adults presenting to an outpatient clinic in Durban, South Africa. 
12 Kocholla L, Wangai M, Kusu N, Manudu J, Thuo M. Reasons for switching highly 
active antiretroviral therapy (HAART) regimen among HIV/AIDS patients in low-
resource settings: the case of Mbagathi District  Hospital, Kenya. 
13 Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment 
change after starting highly active antiretroviral therapy in antiretroviral-naïve 
patient. HIV Med. 2007 Apr; 8(3):186-91. 
14 Weidle PJ, Lichtenstein KA, Moorman AC, BargenJC. Factors associated with 
successful modification of antiretroviral therapy. AIDS 2000; 14 (5):491-497. 
15 Manfredi R, Chiodo F. Substitution of protease inhibitors during treatment of 
patients with human immunodeficiency virus infection: frequency, mode, 
reasons and mid-term outcome. J AntimicrobChemother 2000; 45: 261-263. 
16  Klein MB,  Willemont P, Murphy T, Lalonde RG. The impact of initial highly active 
antiretroviral therapy on future treatment sequences in HIV infection. AIDS, 2000; 18 
(14): 1895-1904. 
17 Kaiser Family Foundation. 2007. The multi-sectoral impact of the HIV/AIDS 
epidemic--a primer. Available from: www.kff.org/hivaids/upload/7661.pdf 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
20 
 
 
 
25 
 
Stellenbosch University  https://scholar.sun.ac.za
21 
 
26 
Stellenbosch University  https://scholar.sun.ac.za
22 
 
 
 
27 
 
Stellenbosch University  https://scholar.sun.ac.za
23 
 
 
28 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
 
 
 
 
DATA COLLECTION SHEET 
 
NO AGE GENDER 
DATE PT  REGIMEN DATE RX REASON CHANGED 
DURATION 
ON  
STARTED STARTED CHANGED/ FOR TREATMENT INITIAL Rx 
TREATMENT   MODIFIED CHANGE     
1             
 
  
              
 
  
 2                 
                  
3             
 
  
                  
 4                 
                  
 5                 
                  
6                 
                  
 7                 
                  
 8                 
                  
 9                 
                  
 10                 
                  
 11                 
                  
12                 
                  
 13                 
                  
 14                 
                  
15                 
                  
          
 
  
Stellenbosch University  https://scholar.sun.ac.za
25 
 
 
Stellenbosch University  https://scholar.sun.ac.za
